GSK plc (GSK)

1,415.40
+8.60(+0.61%)
  • Volume:
    4,228,233
  • Bid/Ask:
    1,380.00/1,440.00
  • Day's Range:
    1,399.20 - 1,422.00
High dividend Yield

Dividend yield shows how much a company pays its shareholders in dividends annually per dollar invested. It reflects how much an investor will earn aside from any capital gains in the stock.

GSK Overview

Prev. Close
1,406.8
Day's Range
1,399.2-1,422
Revenue
28.58B
Open
1,412.6
52 wk Range
1,280.92-1,842.76
EPS
3.41
Volume
4,228,233
Market Cap
57.1B
Dividend (Yield)
76.25
(5.38%)
Average Volume (3m)
7,986,241
P/E Ratio
14.06
Beta
0.323
1-Year Change
-9.08%
Shares Outstanding
4,034,198,564
Next Earnings Date
01 Feb 2023
What is your sentiment on GSK plc?
or
Market is currently closed. Voting is open during market hours.

GSK plc News

GSK plc Analysis

GSK plc Company Profile

GSK plc Company Profile

Employees
90096

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
  • ITH stock
    0
    • Bought back all the gsk that I sold back in May. It's a no brainer at this price
      0
      • You are right. Also the price has been range bound for a decade and we are now near to the lower bound. I've heard similar comments to you nearly ever year when it's price is underperforming
        0
      • I wish the institutional shareholders would wake up and do something about the management team. Surely with such an abysmal performance over so long GSK must be a takeover target?
        0
      • I'm only interested in swing trading this counter. If the price doesn't move I'll just collect dividends while waiting for it to bounce. The spinoff of Haleon is a good move as in this day and age companies need to be pure play to get ahead of competition. Consumer healthcare business was a distraction to their management.
        0
    • new management required
      0
      • Bloodbath coming
        3
        • Hi John, it will be worsth ?
          0
        • When will this carnage start, exacty (02/11/22)
          0
      • Should have taken the Unilever offer...
        0
        • It was madness not to.
          0
      • Demerger yet another damp squib in a long line of failures by Walmsley. She is unprecedented in her ability to talk the talk but to not walk the walk!
        2
        • This may go up further but I've started to take some profit as precaution. I suspect ulvr may not revise their offer after its sp tanking showing clear sentiments from shareholding to reject this move
          2
          • Moving closer to my 1800 tgt (posted on March 30). This stock pays very generous dividend I have to say
            4
            • ex-div in 13 days time. why risk selling now when you might not get back on the boat? pretty sure the company split will reach equivalent of 2000+ for the two new companies.
              1
              • 1587.80 looking at my previous comment "what do i know" near yearly HIGHS
                0